1 Inhalation of vanadium compounds, particularly vanadate, is a cause of occupational bronchial asthma. We have now studied the action of vanadate on human isolated bronchus. Vanadate (0.1 mM ± 3 mM) produced concentration-dependent, well-sustained contraction. Its 7logEC 50 was 3.74+0.05 (mean+s.e.mean) and its maximal eect was equivalent to 97.5+4.2% of the response to acetylcholine (ACh, 1 mM). 2 Vanadate (200 mM)-induced contraction of human bronchus was epithelium-independent and was not inhibited by indomethacin (2.8 mM), zileuton (10 mM), a mixture of atropine, mepyramine and phentolamine (each at 1 mM), or by mast cell degranulation with compound 48/80. . The tissue content of Na + was increased and the tissue content of K + was decreased by ouabain (10 mM). In contrast, vanadate (200 mM) did not alter the tissue content of these ions. Tissue incubation in a Na + -de®cient (25 mM) PSS or in PSS containing amiloride (0.1 mM) markedly inhibited the spasmogenic eect of vanadate (200 mM). 5 Vanadate (200 mM)-induced contractions were markedly reduced by tissue treatment with each of the protein kinase C (PKC) inhibitors H-7 (10 mM), staurosporine (1 mM) and calphostin C (1 mM). Genistein (100 mM), an inhibitor of protein tyrosine kinase, also reduced the response to vanadate. 6 Vanadate (0.1 ± 3 mM) and ACh (1 mM ± 3 mM) each increased inositol phosphate accumulation in bronchus. Such responses were unaected by a Ca 2+ -free medium either alone or in combination with ryanodine (10 mM). 7 In human cultured tracheal smooth muscle cells, histamine (100 mM) and vanadate (200 mM) each produced a transient increase in intracellular Ca 2+ concentration ([Ca 2+ ] i ). 8 Intracellular microelectrode recording showed that the contractile eect of vanadate (200 mM) in human bronchus was associated with cellular depolarization. 9 It is concluded that vanadate acts directly on human bronchial smooth muscle, promoting the release of Ca 2+ from an intracellular store. The Ca 2+ release mechanism involves both the production of inositol phosphate second messengers and inhibition of Ca-ATPase. The activation of PKC plays an important role in mediating vanadate-induced contraction at values of [Ca
Introduction
Occupational inhalation of airborne vanadium compounds, particularly vanadate which is the predominant species in the body¯uids (Nechay, 1984) , causes bronchial asthma (US Department of Health, Education and Welfare Report, 1977; Musk & Tees, 1982) . In the anaesthetized guinea-pig, vanadate produces bronchoconstriction (Nayler & Mitchell, 1987) . It has been suggested from clinical (Musk & Tees, 1982) and animal (Nayler & Mitchell, 1987) studies that the pulmonary eects of vanadate involve a direct action on the smooth muscle of airways. Other actions of an immuological (Zenz et al., 1962) or a neurogenic (Nayler & Mitchell, 1987) nature may also play a role. Vanadate contracts tracheal smooth muscle isolated from the guinea-pig (Nayler & Sparrow, 1983; Cortijo et al., 1993b) , dog (Lee et al., 1994) , and monkey and rabbit (Ueda et al., 1985) . Vanadate has a variety of actions in vitro but the principal mechanism of vanadate-induced contraction of guinea-pig trachea appears to be intracellular Ca 2+ mobilization linked to inhibition of Ca 2+ -dependent ATPase activity (Nayler & Sparrow, 1983) .
Although the in vitro eects of vanadate have been studied in various airway smooth muscle preparations derived from experimental animals, its eects on human isolated airway smooth muscle have not yet been studied. The aim of the present study was to examine the mechanical, biochemical and electrophysiological eects of vanadate in human isolated bronchus. A preliminary account of part of this work has been communicated to the British Pharmacological Society (Morcillo et al., 1995).
Methods

Preparation of human tissues for pharmacomechanical experiments
Lung tissue was obtained from patients who were undergoing surgery for lung carcinoma. None of the patients had a history of asthma. After the resection of one or more lung lobes, a piece of macroscopically normal tissue was excised and immersed in physiological salt solution (PSS, for composition see drugs and solutions) at 48C for transport to the laboratory. Parts of the bronchus were then dissected free from parenchymal tissue and preparations cut (3 ± 4 mm length63 ± 4 mm internal diameter) as previously described (Cortijo et al., 1993a) . Preparations were stored in PSS, equilibrated with 5% CO 2 in O 2 at 48C until use. Experiments were routinely completed within 24 h of initial tissue storage.
Bronchial rings were set up in 10 ml organ baths containing PSS, gassed with 5% CO 2 in O 2 at 378C (pH 7.4). Each preparation was connected to a force displacement transducer (Grass FTO3) and isometric tension changes were recorded on a Grass polygraph (model 7P). The preparations were equilibrated for 60 ± 90 min (with changes in bath¯uid every 20 min) before any pharmacological intervention occurred. Imposed tension of 2 g was maintained throughout the equilibration period and a stable resting level of tone was present at the end of this period. In all experiments, strips of human bronchus were initially challenged with acetylcholine (ACh, 1 mM) in order to determine the maximal contractile response of the tissue.
Assessment of the eect of vanadate on spontaneous bronchial tone and its modi®cation by drugs and other interventions
A cumulative concentration-response curve for vanadate (0.1 mM ± 3 mM) was constructed. In some tissues, a second concentration-response curve for vanadate was obtained following a wash out period of 30 min. A concentration of vanadate (200 mM) close to its EC 50 was selected for further experiments. The response to this concentration of vanadate was monitored for 60 min both in time-matched control tissues and in test tissues. Test tissues were subjected to epithelial removal (Iriarte et al., 1990) or were treated with an agent such as indomethacin (2.8 mM), zileuton (10 mM), compound 48/80 (two consecutive 30 min challenges each at a concentration of 100 mg ml 71 ), a mixture of atropine, phentolamine and mepyramine (each at 1 mM), verapamil (1 mM), nifedipine (1 mM), ouabain (10 mM), amiloride (100 mM), H-7 (10 mM), staurosporine (1 mM), calphostin C (1 mM), or genistein (100 mM). With the exception of compound 48/80, the response of test tissues to vanadate was obtained after 30 min preincubation with, and in the presence of, the relevant drug treatment.
The response of test tissues to vanadate was also measured in preparations bathed in modi®ed solutions: Ca 2+ -free PSS containing EGTA (0.1 mM), K + -rich (80 mM) PSS, K + -free PSS, and Na + -de®cient (25 mM) PSS (for composition see drugs and solutions). In general, test tissues were exposed to the modi®ed solutions for 30 min before and throughout the vanadate challenge. In the case of the Na + -de®cient PSS, the preincubation time was increased to 60 min. To assess the effect of vanadate on K + -induced relaxation, the tissues were incubated for 30 min in K + -free PSS then, for test tissues, the bath¯uid was exchanged for K + -free PSS containing vanadate (200 mM) or ouabain (10 mM). Fifteen minutes later test tissues were challenged with KCl (30 mM). Time-matched control tissues were subjected to the same protocol but were not exposed to vanadate or ouabain.
In further experiments, the response of test tissues to vanadate (200 mM) was measured after 30 min preincubation with, and in the presence of, Ca 2+ -free PSS containing both EGTA (0.1 mM) and ryanodine (10 mM). In experiments involving the depletion and re®lling of internal Ca 2+ stores, three consecutive challenges with vanadate (200 mM, applied for 15 min) were made at 30 min intervals in the presence of Ca 2+ -free EGTA (1 mM) PSS. In the case of test tissues, cyclopiazonic acid (CPA; 10 mM) was then added to the medium and remained present for the duration of the experiment. Twenty minutes later, the medium was changed for a K + -rich (80 mM), Ca 2+ (2.5 mM)-containing PSS and 50 min later, the medium was changed back to the Ca 2+ -free EGTA (1 mM)-containing PSS and a fourth vanadate challenge was made. Control tissues were treated identically to test tissues except that they were not exposed to CPA. In further experiments the mechanical eects of CPA (10 mM) were studied by its addition to strips of bronchus bathed by normal PSS.
Assessment of tissue ion content
Tissue Na + and K + contents were determined by a modi®ed lithium method, essentially as described for rabbit and monkey trachea by Ueda et al. (1985) . After 60 min incubation with PSS (control tissues), ouabain (10 mM) or vanadate (200 mM), bronchial strips (wet weight approximately 25 mg) were washed for 30 min with cold Li + solution (composition in mM: LiCl 142.2, CaCl 2 2.5, MgCl 2 1.0, LiHCO 3 11.9 and glucose 5.5). Tissues were then blotted on ®lter paper, weighed, digested overnight with 0.5 ml of a 1 : 1 mixture of HClO 4 (60% w/v) and HNO 3 (61% w/v) at 1808C. The residue was dissolved in 0.01 N HCl. The Na + and K + contents of this solution were determined by atomic absorption spectrophotometry (PerkinElmer 2380).
Eects of ACh and vanadate on inositol phosphate accumulation
Total inositol phosphate accumulation was determined as previously outlined (Chulia et al., 1996) . In short, cryostored human bronchi (7808C, in foetal calf serum containing 1.8 M dimethylsulphoxide (DMSO) Sarria et al., 1995) from 2 to 5 patients were rapidly thawed in a 378C water bath and rinsed in a large volume of PSS to eliminate the DMSO. They were cut into small fragments (about 1 mm 2 ) and the pool, weighing a total of *10 g was washed in PSS and incubated in 25 ml PSS containing 50 mCi of myo-[
3 H]-inositol for 4 h at 378C. After this incubation, the tissue was washed twice with PSS. Aliquots of washed tissue (1 ± 1.5 g) were placed in a 2 ml ®nal volume of PSS and preincubated at 378C for 30 min (for Ca 2+ -free experiments, the tissue was rinsed and preincubated for 30 min in Ca 2+ -free EGTA 0.1 mM PSS with or without ryanodine). Just before stimulation, 20 ml of LiCl was added (®nal concentration 10 mM). The samples were then stimulated with 20 ml PSS (control), acetylcholine (1 mM ± 3 mM; values for 3 mM served as reference values of 100%) or vanadate (0.1, 0.3, 1 or 3 mM) for 30 min at 378C. Stimulation was stopped by addition of 3 ml of ice-cold mixture of chloroform/methanol/HCl 12 M (100 : 200 : 4, v/v/v) and vigorous shaking. The samples were centrifuged (4000 g) for 10 min at 48C and the aqueous phases were brought to pH 4 and stored at 7208C until analysis. The separation of inositol phosphates was performed by a high performance liquid chromatography (h.p.l.c.) ion-exchange system (linear gradient of potassium phosphate 1 M, pH 3.7), and the radioactivity measured in a Flow-One on-line radioactivity detector (Packard, Meriden, U.S.A.) as described by Chulia et al. (1996) . ), streptomycin (100 mg ml 71 ) and amphotericin B (2.5 mg ml
71
); 1 ± 2 g of wet tissue was minced and washed in supplemented DMEM. The tissue slurry was centrifuged at 150 g for 5 min at 48C. The pellet was resuspended in 10 ml of DMEM containing 640 u ml 71 collagenase (type IV, Sigma) and 10 u ml 71 elastase (type I, Sigma), and digested for 90 min in a shaking bath at 378C. The cell suspension was ®ltered and centrifuged at 150 g for 10 min, resuspended in DMEM/ Ham's F12 medium supplemented as indicated above, counted in a haemocytometer, and viability assessed by trypan blue exclusion (495%). Cell suspensions were plated in 25 cm 2 asks at 378C in a humidi®ed atmosphere of 5% CO 2 in air, with fresh medium exchanged at 48 ± 72 h intervals. Cells were subcultured after reaching con¯uency (*21 days). Subculturing was performed for up to 4 ± 5 passages. Cells in subcultures were examined with a monoclonal antibody against smooth muscle actin (1 :100 dilution; Sigma) using the avidin-biotinperoxidase method (Hsu et al., 1981) ; 495% of the cells were positively stained. Measurements of [Ca 2+ ] i were performed on cell suspensions essentially as described previously (Cortijo et al., 1996) . Brie¯y, human tracheal smooth muscle cells cultured in 25 cm 2¯a sks were incubated with 3 M fura-2/AM (3 mM stock solution in dimethylsulphoxide), at 378C for 45 min in HEPES buer (composition, mM: NaCl 145, KCl 5, MgSO 4 1, HEPES 10, CaCl 2 2, glucose 10, pH 7.45). The cells were then washed with this buer and incubated for 15 min in the absence of fura-2. The cells were detached with trypsin (2 min at 378C) and washed with HEPES buer. Fura-2 loaded cells were resuspended at 10 6 cells ml 71 and placed in 1 cm quartz cuvettes. Cells in cuvettes were pre-incubated for 2 min at 378C, with gentle stirring, in a temperature-controlled cuvette holder before¯uorescence intensities were measured with a Perkin-Elmer LS-50 spectro¯uorimeter. Vanadate (200 mM) or histamine (100 mM) was added in a volume of 20 ml to 1 ml cell suspension and the changes were monitored for 30 min (vanadate) or 4 min (histamine). [Ca 2+ ] i was calculated from the¯uorescence intensities measured at 510 nm after excitation at 340 and 380 nm as described by Grynkiewicz et al. (1985) . Maximum and minimum¯uorescence intensities were obtained with 0.1% Triton X-100 and 10 mM EGTA in 2 M TrisHCl, pH 8.5, respectively.
Electrophysiological studies
The tissue bath used and other technical aspects have been described previously (Small & Weston, 1979; Dixon & Small, 1983) . The mucosal membrane covering the luminal surface of the bronchus was carefully removed with a cotton bud and the tissue was set up for the simultaneous recording of intracellular electrical activity and mechanical changes. Microelectrodes (30 ± 50 MO: tip potentials of less than 5 mV) were ®lled with 3 M KCl and were used in conjunction with a WPI Intra 767 ampli®er. One or two preparations from each patient (a total of 15 preparations from 8 patients) were examined. In 5 preparations from 4 patients, vanadate (200 mM) was added to the superfusing PSS and changes in membrane potential and tension were monitored for 10 min.
Drugs and solutions; statistical analysis of results
Drug concentrations are expressed as ®nal bath concentrations of the active species. The following drugs were used: acetylcholine chloride, atropine sulphate, calphostin C, cyclopiazonic acid (CPA), ethyleneglycol-bis-(b-amino-ethyl-ether)-N-N'-tetraacetic acid (EGTA), genistein, H-7 (1-(5-isoquinolinylsulphonyl)-2-methyl-piperazine), histamine hydrochloride, indomethacin, mepyramine maleate, ouabain, phentolamine hydrochloride, staurosporine, sodium metavanadate (each from Sigma), amiloride hydrochloride (Merck, Sharp & Dohme), (+)-verapamil hydrochloride (Biosedra-Knoll), ryanodine (Calbiochem) and zileuton (gift from Dr S.A. Esteve). Other chemicals used were of analytical grade (E. Merck; Panreac). Stock solutions of calphostin C, CPA and genistein were prepared in dimethyl sulphoxide (DMSO). Stock solutions of indomethacin, ryanodine, nifedipine and zileuton were prepared in absolute ethanol. Final bath concentrations of the solvents did not themselves aect the mechanical activity of the tissue. Calphostin C, nifedipine and staurosporine were protected from light exposure. Other drugs were dissolved in PSS just before use. The composition (mM) of the physiological salt solution (PSS) was: NaCl 118.4, KCl 4.7, CaCl 2 2.5, MgSO 4 0.6, KH 2 PO 4 1.2, NaHCO 3 25.0 and glucose 11.1. The Ca 2+ -free PSS was prepared by substituting EGTA (0.1 mM) for CaCl 2 . The K + -free PSS was prepared by removing KCl from the PSS and replacing KH 2 PO 4 with NaH 2 PO 4 . The K + -rich (80 mM) PSS was prepared by raising the KCl concentration by 78.8 mM and reducing the concentration of NaCl to preserve isomolality. The Na + -de®cient (25 mM) PSS was prepared by iso-osmotic replacement of NaCl by sucrose.
Contractile responses are expressed in absolute values (g or mg) and/or as a percentage of the response to ACh (1 mM). The EC 50 of spasmogens was derived by interpolation in each concentration-eect curve. Data are presented as means+ s.e.mean. The number of experiments is expressed as`n/p' where n represents the number of preparations examined, and p the number of patients from which those tissues were derived. Statistical analysis of the results was performed by analysis of variance followed by Bonferroni multiple comparison test or by Student's t test as appropriate. Dierences were considered signi®cant when P50.05.
Results
Contraction of human bronchus induced by vanadate
Vanadate (0.1 mM ± 3 mM) applied cumulatively to human isolated bronchus caused concentration-dependent tension development ( Figure 1 ). The maximal eect of vanadate was 1.69+0.27 g tension (mean+s.e.mean) which was equivalent to 97.5+4.2% (n/p=7/4) of the contraction elicited by ACh (1 mM). The 7logEC 50 for vanadate was 3.74+0.05 (n/p= 7/4). A concentration of vanadate (200 mM) close to its EC 50 was selected for further experiments. The onset of tension development in response to vanadate (200 mM) occurred within 1 min of challenge and maximum tension was achieved after 25 ± 45 min (Figure 2 ). This tension was maintained for periods in excess of 60 min. Responses to vanadate were reversible following washout and reproducible contractions could be elicited at 30 min intervals (data not shown).
Role of epithelium and endogenous mediators in vanadate-induced contractions
Removal of the epithelium did not alter the response of the tissue strips to vanadate (200 mM) ( Table 1) . Tissue incubation with either indomethacin (2.8 mM) or zileuton (10 mM) for 30 min had no eects on basal tone. Furthermore, neither indomethacin nor zileuton modi®ed the contractile response to vanadate (200 mM) ( Table 1 ). The initial exposure of bronchial strips to compound 48/80 (100 mg ml 71 ) induced a contraction equivalent to 53.8+6.3% of that evoked by ACh (1 mM; n/p=6/4), but the response to the second challenge with 48/80 was only 12.3+5.2% (n/p=6/4) of the response evoked by ACh. The contractile response to vanadate in tissues twicechallenged with compound 48/80 did not dier from that seen in time-matched control tissues (Table 1) . Similarly, the contractile response to vanadate was unaltered by tissue treatment with a mixture of atropine (1 mM), phentolamine (1 mM) and mepyramine (1 mM) ( Table 1) .
Eect of extracellular Ca
2+ , Ca 2+ channel blockers, ryanodine and cyclopiazonic acid on vanadate-induced contraction Verapamil (1 mM) and nifedipine (1 mM) reduced the spontaneous tone of the tissues by 378+82 mg and 314+122 mg respectively (n/p=6/4). However, tissue treatment with either of these inhibitors of Ca 2+ in¯ux failed to reduce the contractile eect of vanadate (200 mM) (Table 1) . Baseline tension fell (by 842+146 mg; n/p=9/5) when PSS was changed to a Ca 2+ -free PSS containing EGTA (0.1 mM). Vanadate (200 mM) contractions elicited after 60 min incubation in the Ca 2+ -free, EGTA-containing PSS were of amplitude and time course similar to those observed in time-matched control tissues bathed by normal PSS (Figure 2a) . In some tissues the addition of ryanodine (10 mM) to the Ca 2+ -free, EGTA-containing PSS caused a small, transient contraction. However, ryanodine did not otherwise modify the tissue tone loss induced by the Ca 2+ -free medium. The addition of ryanodine to the Ca 2+ -free medium signi®cantly reduced the contractile response to vanadate (200 mM) (Figure 2a and Table 1 ). In experiments involving the depletion and re®lling of intracellular Ca 2+ stores, the response to the third vanadate challenge in the Ca 2+ -free, EGTA (1 mM)-containing PSS was signi®-cantly smaller than the response to the initial challenge ( Table  2) . Exposure of control tissues to the Ca 2+ (2.5 mM)-containing, K + -rich (80 mM) PSS restored the response to vanadate, the response to the fourth vanadate challenge (made in the Ca 2+ -free EGTA-containing medium) did not dier from the response to the initial challenge. In test tissues, the third response to vanadate was similarly reduced compared with the response to the initial challenge. However, the presence of CPA (10 mM) during the Ca 2+ store re®lling process blocked the recovery of the response to vanadate. The test tissue response to the fourth vanadate challenge was signi®cantly smaller than the response to the initial challenge. It was also signi®cantly smaller than the response to the fourth challenge in the control tissues (Table 2 ). Added to bronchial strips bathed by normal PSS, CPA (10 mM) evoked tension development. Peak tension was reached after approximately 10 min and was equivalent to 83.9+5.3% of the ACh maximum (n/p=3/2). Eect of inhibitors of protein kinase C and protein tyrosine kinase on vanadate-induced contraction Staurosporine (1 mM) did not aect the spontaneous tone of human bronchus (n/p=6/3). However, H-7 (10 mM) and calphostin C (1 mM) reduced tone by 569+106 mg (n/p=6/3) and 291+62 mg (n/p=6/3) respectively. H-7, staurosporine and calphostin C each inhibited the contraction to vanadate (200 mM) (Figure 2b ). Genistein (100 mM) reduced spontaneous tone by 1.08+0.94 g (n/p=8/3) and reduced (by approximately 30%) the contraction to vanadate (Table 1) .
Eect of extracellular K + on vanadate-induced contraction
Human bronchus contracted on exposure to K + (80 mM)-rich PSS with peak tension (71.9+4.6% of the maximal response to ACh) being attained within 10 min, followed by a slow decline to a lower level (23.2+1.6% of the maximal response to ACh). After 30 min tissue incubation in K + -rich PSS, vanadate (200 mM) induced contractions for which the peak amplitude and time course were similar to those observed in control tissues bathed by normal PSS (Table 1) . Exposure of bronchial strips to a K + -free PSS resulted in a reduction in baseline tension followed by recovery to preexposure levels 30 min later (Figure 3a) . The subsequent addition of ouabain (10 mM) or vanadate (200 mM) evoked a contraction (Figure 3a) . In the ®nal stages of the experiments involving K + -free, PSS, KCl (30 mM) was added to the bath¯uid. In the time-matched control tissues this readmission of K + evoked a transient relaxation followed by a rise in tension above the pre-existing level. In test tissues that had been treated with ouabain (10 mM), the readmission of K + evoked contraction only. In contrast, test tissues that had been treated with vanadate responded to the readmission of K + with transient relaxation followed by contraction (Figure 3a) .
Eect of Na
+ -de®cient PSS, amiloride and ouabain on vanadate-induced contraction
Exposure to a Na + -de®cient (25 mM) PSS evoked a contraction which, after a period of 4 ± 5 min, was equivalent to 49+6% of the response to ACh (1 mM). This contraction then faded with return to baseline tension occurring after 50 ± 60 min. Similarly, tissue treatment with amiloride (0.1 mM) evoked a transient contraction of peak value equivalent to 18+7% of the response to ACh (1 mM). Tissue tension returned to the pre-existing baseline within 25 ± 30 min. Vanadate (200 mM)-induced contraction was signi®cantly depressed in tissues bathed in a low Na + solution or treated with amiloride (Table 1 and Figure 3b ). In contrast, Na + -de®cient (25 mM) PSS and amiloride (0.1 mM) each failed to modify (control response=67.3+3.6% of ACh maximal eect, response in Na + -de®cient PSS=66.5+5.4% and response after amiloride=58.7+6.3%; P40.05 and n/p=5/3) contractile responses to ACh (50 mM). Ouabain (10 mM) evoked a sustained contraction equivalent to 43.3+5.7% (n/p=6/5) of the response to ACh (1 mM). This contraction was not observed in tissues subjected to 30 min preincubation in Ca 2+ -free, EGTA (0.1 mM)-containing PSS. Vanadate (200 mM)-induced contraction was unaltered by tissue treatment with ouabain (10 mM) ( Table 1) .
Eects of ouabain and vanadate on the tissue content of Na + and K + Ouabain (10 mM) increased the Na + content but decreased the K + content of the human bronchial strips. Vanadate (200 mM) did not signi®cantly modify either the Na + or the K + content of the tissue (Table 3) .
Eects of vanadate on inositol phosphates
ACh (3 mM) and vanadate (3 mM) each caused time-dependent accumulation of inositol phosphates in bronchus. For each agonist, inositol phosphate accumulation increased Data represent responses (mean+s.e.mean) to vandate expressed as a percentage of the contractile response to ACh (1 mM). n=number of bronchial strips and p=number of patients from which the bronchial strips were derived. The eects of ryanodine (10 mM) were examined in experiments where both the test and time-matched control tissues were bathed by Ca 2+ -free, EGTA (0.1 mM)-containing PSS. The experiments with a Ca 2 -free medium, a Na + -de®cient medium and an amiloride-containing medium were performed concurrently and hence used a common group of control tissues. *Signi®cant (P50.05) dierence from the control value. linearly over a period of 60 min and no saturation of accumulation was oberved (data not shown). When inositol phosphate accumulation was measured 30 min after agonist challenge, ACh (1 mM ± 3 mM) and vanadate (100 mM ± 3 mM) were each found to increase inositol phosphate accumulation in a concentration-dependent manner (Figure 4a ). In contrast to ACh, the maximal eect of vanadate was not reached, even at a concentration of 3 mM. When equal concentrations were compared, the inositol phosphate accumulation produced by vanadate was signi®cantly smaller than that evoked by ACh (Figure 4a ). The accumulation of inositol phosphates induced either by vanadate or by ACh was unaected by tissue exposure to Ca
2+
-free EGTA 0.1 mM PSS with or without ryanodine (10 mM) (Figure 4b ).
Eects of vanadate on [Ca 2+ ] i
Histamine (100 mM) evoked contraction of human bronchus equivalent to that evoked by vanadate (200 mM). This concentration of histamine increased the [Ca 2+ ] i of cultured tracheal smooth muscle cells from a basal value of 97.0+14.3 nM to a peak value of 366.7+36.6 nM (n/p=7/4). ] i returned to the basal level within the next 10 s.
Electrophysiological studies
The resting membrane potential of the human bronchial muscle was 745.7+1.3 mV (range 736 mV to 752 mV; n/p=15/8). In 5 out of 15 cells examined, spontaneous slow, oscillatory potential changes (slow waves) were recorded. These slow waves occurred at a frequency of 29.2+3.3 min 71 and were of variable amplitude (1 ± 5 mV in one cell, 10 ± 15 mV in the remainder). The other cells exhibited irregular potential changes of small amplitude (1 ± 5 mV) and, in one case, these irregular potential changes were interrupted by bursts of more regular slow waves. The resting membrane potential in cells subsequently exposed to vanadate was 742.8+2.1 mV (n/p=5/4). The addition of vanadate (200 mM) to the superfusate reduced the amplitude of the oscillatory slow waves and evoked depolarization (25.4+1.9 mV; n/p=5/4). These electrical changes were accompanied by an increase (640+154 mg) in tissue tension ( Figure 5 ).
Discussion
Direct basis of vanadate-induced contraction in human bronchus
The spasmogenic action of vanadate in human bronchus does not result from stimulation of prostaglandin synthesis since indomethacin (2.8 mM, a concentration sucient to block prostaglandin synthesis by human bronchial tissue; Brink et al., 1980) failed to antagonize vanadate (Table 1) . Zileuton (10 mM) is known markedly to inhibit the activity of 5-lipoxygenase in human tissue (McMillan et al., 1992) . The failure of zileuton to antagonize vanadate-induced spasm of human bronchus ( Table 1 ) therefore suggests that vanadate does not act to stimulate leukotriene production. The resistance of vanadate-induced spasm to both atropine (1 mM) and phentolamine (1 mM) (Table 1) suggests that such spasm is not mediated by the release of parasympathetic or sympathetic neurotransmitters. Tissue treatment with either compound 48/80 or with mepyramine (1 mM) did not modify the action of vanadate (Table 1) . These two ®ndings suggest that the spasmogenic action of vanadate is not mediated by the release of histamine from mast cells. Furthermore epithelial removal did not modify the action of vanadate (Table 1) . Therefore, the spasmogenic action of vanadate in human bronchus is unlikely to involve the release of mediators from structures within the bronchial wall but, instead, re¯ects a direct eect of vanadate on the smooth muscle cells. vanadate was observed to cause contraction of human trachealis with a potency and time course similar to those observed in bronchus. The rise in [Ca 2+ ] i evoked by vanadate in human trachealis cells was very transient. A similar response was described by Sandirasegarane & Gopalakrishnan (1995) for vanadate acting on cultured aortic smooth muscle cells. In human bronchus it is dicult to ascribe an activator role to this brief increase in [Ca 2+ ] i because it did not evoke an early phasic, component in the mechanical response. The mechanical responses to vanadate developed slowly, was monophasic and, for the vast majority of its time course, was associated with a value of [Ca 2+ ] i that was not signi®cantly dierent from the basal value. We therefore presume that the activator Ca 2+ utilized by vanadate either comprises discrete, very localized increases in [Ca 2+ ] within the cell or comprises a more widespread, but very small, increase in [Ca 2+ ] i . In either case such events could have been below the limits of detection of our method of measuring [Ca 2+ ]. Verapamil and nifedipine can inhibit Ca 2+ in¯ux through L-type channels in airway smooth muscle cells (Drazen et al., 1983; Kohrogi et al., 1985; Black et al., 1986) . The failure of these two agents to reduce vanadate-induced contraction (Table 1) indicates that the spasmogenic action of vanadate does not involve promotion of Ca 2+ in¯ux through such channels. It might be argued that vanadate acts, instead, to promote Ca 2+ in¯ux through channels resistant to these agents. However, the contraction of human isolated bronchus induced by vanadate was unaected by tissue exposure to a Ca 2+ -free PSS containing EGTA (0.1 or 1 mM). Such concentrations of EGTA are envisaged to chelate extracellular Ca 2+ and Ca 2+ bound at super®cial sites on the plasmalemma, but to leave the intracellular stores of Ca 2+ largely intact. Hence, the failure of the EGTA-containing, Ca 2+ -free PSS to suppress vanadate-induced contraction suggests that such contraction does not depend on an extracellularlylocated source of activator Ca 2+ or on the release of Ca 2+ from a super®cial pool that is accessible to EGTA. This ®nding contrasts with the results of studies on airways smooth muscle from laboratory animals where vanadate-induced contraction was markedly reduced in a Ca
Eects of vanadate on [
2+
-free medium (Nayler & Sparrow, 1983; Ueda et al., 1985; Cortijo et al., 1993b; Lee et al., 1994) . It may be that these contrasting results re¯ect dierent sources of activator Ca 2+ for vanadate in human and animal airways smooth muscle. Alternatively, they may re¯ect dierences in the susceptibility of the intracellular Ca 2+ stores to depletion by the Ca 2+ -free, EGTA-containing medium.
That vanadate utilizes an intracellular source of activator Ca 2+ in human bronchial smooth muscle is also suggested by the present experiments with amiloride or a PSS de®cient in Na + . Blaustein (1989) proposed that a Na + /Ca 2+ antiporter exists in airways smooth muscle. This Na + /Ca 2+ antiporter is located in regions of the smooth muscle cell membrane, that are in close apposition to the endoplasmic reticulum, and plays an important role in maintaining the Ca 2+ content of the intracellular store (Moore et al., 1993) . Amiloride inhibits the Na + /Ca 2+ antiporter (Bova et al., 1988) . Such an action could lead to a reduction in the cellular extrusion of Ca 2+ and could explain the present ®nding that amiloride caused contraction of human bronchus. Exposure of smooth muscle to a Na + -de®cient PSS can evoke a reverse-mode action of the Na + /Ca 2+ antiporter (Ohata et al., 1996) and may explain our ®nding that such a medium also induced contraction. In the long term, tissue exposure to a Na + -de®cient PSS would result in a reduction in [Na + ] i . In this situation the Na + /Ca 2+ antiporter would be compromised and the intracellular Ca 2+ store would become depleted (Brading et al., 1980) . Tissue treatment with amiloride would have the same end eect. The present ®ndings that tissue exposure to amiloride and a PSS de®cient in Na + could each reduce the contractile action of vanadate therefore also indicate that vanadate uses an intracellular source of Ca 2+ as an activator.
Ryanodine interferes with Ca 2+ mobilization from the endoplasmic reticulum in a variety of tissues including airway smooth muscle (Ito et al., 1986; Gerthoer et al., 1988; Hay, 1990; Chideckel & Anireddy, 1991) . Ryanodine receptors are located on the cytosolic end of Ca 2+ channels that permeate the membrane of the endoplasmic reticulum. Their activation can promote channel opening in a reduced conductance state, but can also promote irreversible channel closure (Sitsapesan et al., 1995) . It may be that the opening of Ca 2+ channels in the endoplasmic reticulum explains our ®nding that ryanodine evoked transient spasm of human bronchus. The ability of ryanodine to reduce vanadate-induced contraction of bronchus bathed by a Ca 2+ -free, EGTA-containing PSS (Figure 2a and Table 1) suggests that vanadate utilizes activator Ca 2+ that is released from an intracellular store. Since ryanodine did not evoke contraction equivalent to that produced by cyclopiazonic acid (see below), it may be that the principal eect of ryanodine in antagonizing vanadate is not so much to deplete intracellular Ca 2+ stores but more to prevent Ca 2+ release from the stores into the cytosol.
Mechanisms of vanadate-induced release of Ca 2+ from intracellular stores
Vanadate has been shown to inhibit Ca-ATPase in the endoplasmic reticulum of cardiac muscle, skeletal muscle and smooth muscle with a K i value in the range 12 ± 50 mM (Wang et al., 1979; Wibo et al., 1981) . This K i value for vanadate lies within the eective concentration range of vanadate in contracting human bronchus ( Figure 1) . As suggested by Nayler and Sparrow (1983) , inhibition of Ca-ATPase would promote Ca 2+ release from the endoplasmic reticulum. In the present study, cyclopiazonic acid was able to mimic the contractile eects of vanadate, suggesting that inhibition of Ca-ATPase can release sucient Ca 2+ to trigger contraction. However, it is unlikely that inhibition of Ca-ATPase in the endoplasmic reticulum is, alone, sucient to explain the contractile eects of vanadate. For the vast majority of its time course, the contractile eect of vanadate was generated at values of [Ca 2+ ] i that were not signi®cantly dierent from the basal value. This suggests the concomitant operation of mechanisms that increase the sensitivity of the contractile machinery to Ca 2+ (see below).
In addition to inhibiting Ca-ATPase in the endoplasmic reticulum, vanadate may also promote the release of stored Ca 2+ by stimulating the production of inositol phosphate second messengers. In canine trachealis muscle (Lee et al., 1994) and in human bronchus (present study; Figure 4a ) ACh and vanadate each evoked a concentration-dependent increase in the accumulation of inositol phosphates. It is likely that the eect of vanadate on inositol phosphate accumulation stems from its ability to activate phospholipase C (PLC). Three major isoforms (PLCb, PLCg and PLCd) of this enzyme have been described in mammalian cells. PLCb is activated by heterotrimeric G-proteins while PLCg is activated following phosphorylation by protein tyrosine kinase. The mechanisms by which PLCd is activated remain unclear (Rhee & Choi, 1992; Clapham, 1995) .
Vanadate has been shown to activate G-proteins in various tissues by forming a stable complex with guanosine 5'-diphosphate (GDP) at the nucleotide binding site (Krawietz et al., 1982; Paris & Pouyssegur, 1987) . It may therefore be that vanadate can activate PLCb by such a mechanism. Similarly, vanadate has been shown to inhibit phosphotyrosine phosphatase (Swarup et al., 1982) . This would mimic the eect of activating protein tyrosine kinase and would, in turn, activate PLCg. Whether vanadate can also activate PLCd remains to be established.
Since the PLC isoform content of human airway smooth muscle cells has not been documented (Chilvers et al., 1994) , it is dicult to assess the relative roles of PLCb, PLCg and PLCd in mediating the presently-observed contractile eects of vanadate. However, we have generated some evidence to suggest that the activation of PLCg may play only a minor role. In taenia coli and vascular smooth muscle (Di Salvo et al., 1993; Filipeaunu et al., 1995) genistein and other tyrosine kinase inhibitors markedly attenuated vanadate-induced contraction. In contrast, genistein (100 mM, a concentration about ®ve times higher than that required for half-maximal inhibition of protein tyrosine kinase phosphorylation; Akiyama & Ogawara, 1991) produced only a 30% inhibition of vanadate-induced contraction of human bronchus. This suggests that protein tyrosine kinase phosphorylation of PLCg (and other intracellular proteins) is only of limited importance in mediating the spasmogenic eects of vanadate in this tissue.
For agonists that stimulate the hydrolysis of phosphoinositides by PLC, inositol trisphosphate (IP 3 ) is the dominant second-messenger molecule provoking the release of Ca 2+ from intracellular stores (Berridge, 1993; Clapham, 1995) . Several authors (Hashimoto et al., 1985; Katsuyama et al., 1990; Challiss et al., 1992) 
Role of protein kinase C in vanadate-induced contraction of human bronchus
Since vanadate can activate certain of the isoforms of phospholipase C, it is therefore likely to stimulate the production of diacylglycerol, an activator of protein kinase C (PKC). The activation of PKC is involved in the tonic contraction of smooth muscle that can be maintained at, or very near, basal levels of [Ca 2+ ] i (Rasmussen et al., 1987) . Yang and Black (1995) have explored the role of PKC in mediating contractile responses of human bronchus to histamine (10 mM). These authors showed that GF 109203X, a highly selective inhibitor of PKC, did not aect the initial peak tension induced by histamine but reduced the secondary, sustained phase of the response. Yang and Black (1995) concluded that PKC is important in mediating only the latter part of the response to histamine.
In the present study the contractile response to vanadate appeared to be monophasic, the peak tension being reached between 25 ± 45 min ( Figure 2 ) and thereafter being well-sustained. The PKC inhibitors H-7, staurosporine and calphostin reduced vanadate-induced contraction over its entire timecourse (Figure 2b ). Like GF 109203X, calphostin is a highly selective inhibitor of PKC (Kobayashi et al., 1989) . The present ®ndings therefore suggest that mechanisms underlying the contractile responses of human bronchus to vanadate dier from those of responses to histamine. In the case of histamine, PKC seems to be important in mediating only the secondary, sustained phase of the response. However, in the case of vanadate, PKC plays an important role throughout the time course of the response.
Role of plasmalemmal transport mechanisms in the contractile action of vanadate
The plasmalemma of human airway smooth muscle cells contains Na + /K + -ATPase and ouabain, an inhibitor of this enzyme, contracts human isolated trachea and bronchus (Chideckel et al., 1987; Knox et al., 1990; present study) . Vanadate is known to be a potent inhibitor of Na + /K + -ATPase in a number of tissues (Nechay, 1984) and it is possible that inhibition of this enzyme accounts for the vanadate-induced contraction of human bronchus. However, several of the present ®ndings do not support this idea. For example, contraction produced by ouabain was abolished in Ca 2+ -free, EGTA-containing PSS while contraction to vanadate remained unaltered ( (Figure 3 ). This relaxationcontraction sequence may result from the initial eects of the increase in the concentration gradient for K + across the cell membrane followed by the secondary eects of Na + /K + -ATPase inhibition. The contractile response to vanadate remained unaltered in tissue incubated in K + -free solution, a result consistent with the resistance of vanadate-induced contraction to ouabain. Readdition of K + after incubation of human trachea or bronchus in K + -free PSS induces a ouabainsensitive relaxation (Chideckel et al., 1987;  Figure 3 ) that is attributable to the re-activation of Na + /K + -ATPase (Chideckel et al., 1987) . In the present study K + -induced relaxation was fully inhibited by ouabain (10 mM) whilst vanadate (20 mM) had no such eect (Figure 3) . Finally, the present atomic absorbtion spectrophotometry studies (Table 3) showed that while ouabain (10 mM) evoked the changes in tissue Na + content and K + content that might be expected following inhibition of Na + /K + -ATPase, such changes were not observed in response to vanadate. Hence, although vanadate may be a potent inhibitor of Na + /K + -ATPase (Nechay, 1984) in certain tissues, this does not seem to explain its ability to contract human isolated bronchus.
The importance of inhibition of Ca-ATPase in the endoplasmic reticulum to the action of vanadate has been discussed above. However, in muscle tissue of various kinds, vanadate is more potent in inhibiting the Ca-ATPase of the plasmalemma than that of the endoplasmic reticulum (Wang et al., 1979; Caroni & Carafoli, 1981; Wibo et al., 1981) . It is thus possible that, by inhibiting the extrusion of Ca 2+ across the plasmalemma mediated by Ca-ATPase, vanadate augments the eects of the Ca 2+ that it releases from the intracellular store.
Role of depolarization in the contractile action of vanadate in human bronchial muscle cells
In the present study the resting membrane potential and the pattern of spontaneous electrical activity of human bronchial smooth muscle cells was similar to that described by Ito et al. (1989) . As discussed above, it seems likely that vanadate acts to promote the release of Ca 2+ from intracellular stores. The depolarization of human isolated bronchus induced by vanadate (200 mM; Figure 5 ) could therefore result from the opening of the Ca 2+ -dependent Cl-channels that have been suggested to exist in the plasmalemma of airways smooth muscle cells (Janssen & Sims, 1992) . However, vanadateinduced depolarization does not appear to be crucial for its spasmogenic action since tissue treatment with a K + -rich (80 mM) PSS did not suppress the mechanical response of human bronchus to vanadate.
Conclusions
It is concluded that vanadate acts directly on human bronchial smooth muscle, promoting the release of Ca 2+ from an intracellular store. This store is maintained by the plasmalemmal Na + /Ca 2+ antiporter and by Ca-ATPase of the endoplasmic reticulum. The process of vanadate-induced Ca 2+ release involves both the production of inositol phosphate second messengers and inhibition of Ca-ATPase. The activation of PKC plays an important role in mediating vanadate-induced contraction which, for most of its time-course, is associated with values of [Ca 2+ ] i that are close to basal. The concentration of vanadium normally found in the human lung is in the range 0.25 ± 2.8 mM (Nechay, 1984) though in city-dwellers this may rise to 78 mM (Tipton & Shafer, 1964) . It is possible that vanadium concentrations in the lungs of workers exposed to vanadium-containing dusts may exceed this value though, as far as we are aware, such data has yet to be published. While lung vanadate concentrations in the range 1 ± 100 mM might be expected directly to cause some contraction of airways smooth muscle (Figure 1 ) it is possible that vanadate, in a lower concentration, may induce airway hyper-reactivity by sensitizing the muscle to other bronchoconstrictor stimuli. This hypothesis awaits the test of further experimentation.
